<DOC>
	<DOCNO>NCT01463059</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety CDP6038 administer subcutaneous ( sc ) various dos compare placebo .</brief_summary>
	<brief_title>Efficacy Safety Olokizumab With Rheumatoid Arthritis With Previously Failed Anti-tumor Necrosis Factor ( Anti-TNF ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Have diagnosis adultonset RA least 6 month ' ( 24 week ) duration define 1987 ACR classification criterion score ≥6 define ACR/European League Against Rheumatism Classification Diagnostic Criteria RA Must moderately severely active RA disease define ≥6 tender joint ( 68joint count ) Screening Baseline , ≥6 swell joint ( 66joint count ) Screening Baseline , CRP ≥1.2 time upper limit normal ( ULN ) ESR &gt; 28mm/hour Must MTX dose 6 16mg/week Japan 7.5 20mg/week Korea Taiwan , stable least 6 week prior Screening stable route administration Must intolerance inadequate response treatment 1 TNFblocker therapy within 2 year Screening Female subject must either postmenopausal least 1 year , surgically incapable childbearing , effectively practice 2 acceptable method contraception Have diagnosis inflammatory arthritis Female subject breastfeeding , pregnant , plan become pregnant study within 24 week Disease modify antirheumatic drug ( DMARDs ) methotrexate ( MTX ) Subjects know concurrent acute chronic viral hepatitis B C infection Subject know tuberculosis ( TB ) disease , high risk acquire TB infection , latent TB infection Subjects know history current clinically active infection Subjects high risk infection Subjects know human immunodeficiency virus ( HIV ) human T cell lymphotropic virus type 1 ( HTLV 1 ) infection Have receive vaccination within 8 week prior Screening plan receive vaccine study ( exception injectable influenza pneumococcal vaccination permit ) Concurrent malignancy history malignancy ( exception successfully treat carcinoma cervix 5 year prior Screening 2 successfully treat basal cell carcinoma within 2 year prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Interleukin-6</keyword>
	<keyword>Olokizumab</keyword>
	<keyword>CDP6038</keyword>
</DOC>